Clearside Biomedical Inc (CLSDQ)
Clearside Biomedical Inc. is a biopharmaceutical company listed on OTC Markets as common stock. The company focuses on developing therapies intended for delivery to the back of the eye through the suprachoroidal space. Its commercial product includes XIPERE, an injectable suspension used for macular edema linked to uveitis. Clearside also develops CLS-AX, an axitinib injectable suspension designed for suprachoroidal administration, which has completed a Phase 2 study in wet age-related macular degeneration. The company has reported collaboration arrangements with Bausch + Lomb Ireland Limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, BioCryst Pharmaceuticals, and Aura Biosciences. Incorporated in 2011 and headquartered in Alpharetta, Georgia, Clearside Biomedical filed a voluntary Chapter 11 reorganization petition in the U.S. Bankruptcy Court for the District of Delaware on November 23, 2025.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-CLSDQ
|
—
|
—
|
—
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
—
|
—
|
-0.7x
|
-0.3x
|
5.4x
|
17.809 M
|
—
|
97.9%
|
87.7%
|
-50.6
|
—
|
83.7%
|
